|
gptkbp:instanceOf
|
alkaloid
anticholinergic drug
|
|
gptkbp:affiliatedWith
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:ATCCode
|
A04AD01
|
|
gptkbp:CASNumber
|
51-34-3
|
|
gptkbp:chemicalFormula
|
C17H21NO4
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
glaucoma
prostatic hypertrophy
|
|
gptkbp:discoveredBy
|
gptkb:Albert_Ladenburg
|
|
gptkbp:discoveredIn
|
1880
|
|
gptkbp:effect
|
gptkb:center
sedation
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:foundIn
|
gptkb:Datura
gptkb:Atropa_belladonna
gptkb:Hyoscyamus_niger
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Skopolamin
|
|
gptkbp:IUPACName
|
(1S,3S,5R,6R,7S,8R)-6,7-epoxy-3-[(S)-tropoyloxy]tropan-7-yl acetate
|
|
gptkbp:KEGGID
|
D00432
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
muscarinic acetylcholine receptor antagonist
|
|
gptkbp:meltingPoint
|
59–62 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
303.35 g/mol
|
|
gptkbp:otherName
|
gptkb:hyoscine
scopolamine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
5184
CHEMBL1200698
DB00747
4997
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
intravenous
|
|
gptkbp:sideEffect
|
confusion
blurred vision
drowsiness
dry mouth
|
|
gptkbp:UNII
|
577I1CFA9H
|
|
gptkbp:usedFor
|
motion sickness
antispasmodic
postoperative nausea and vomiting
antidote for organophosphate poisoning
preanesthetic medication
|
|
gptkbp:bfsParent
|
gptkb:Vlasta_Třešňák
|
|
gptkbp:bfsLayer
|
7
|